The U.S. is in a better place in our response than at any point of the COVID-19 pandemic. However, we need to continue to support the development of a new generation of tools to stay ahead of COVID-19.
With an initial investment of $5 billion, Project NextGen will accelerate and streamline the rapid development of the next generation of vaccines and treatments through public-private collaborations.
Led by ASPR’s BARDA and National Institutes of Health’s NIAID, Project NextGen will coordinate across the federal government and the private sector to advance the pipeline of new, innovative vaccines and therapeutics from labs to clinical trials to potential FDA authorization, approval, and commercial availability for people nationwide.
Areas of Focus
Vaccines that are Easier to Administer and Reduce Spread of the Virus
Mucosal vaccines such as those delivered intranasally, which could have the potential to dramatically reduce infection and transmission, in addition to preventing serious illness and death.
Vaccines that provide broader protection against variants of concern and a longer duration of protection.
Innovative Solutions for Faster, Cheaper, Rapidly Deployable Technologies
Advancing new technologies that will improve access and enable faster, lower cost, rapid, and flexible production of vaccines and therapeutics.
Pan-Corona virus vaccines which protects against several different coronaviruses.
Modernized, More Resilient Treatments
New and more durable monoclonal antibodies that are resilient against new variants as they arise.
Request a TechWatch Meeting
Prior to submitting to the Broad Agency Announcement (BAA), BARDA encourages you to request a TechWatch meeting. A TechWatch meeting provides prospective partners with the opportunity to receive feedback about the potential product or technology from BARDA staff.
Submission of a TechWatch meeting request does not guarantee a meeting or funding.
Request a Meeting